These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2570741)

  • 1. Justifying neuroleptic drug treatment.
    Overall JE; Garza-Trevino E; Rhoades HM; Volkow ND; Cecil S
    Hosp Community Psychiatry; 1989 Jul; 40(7):749-51. PubMed ID: 2570741
    [No Abstract]   [Full Text] [Related]  

  • 2. All antipsychotics are equal, but some are more equal than others.
    Volavka J; Citrome L
    J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.
    Simhandl C; Meszaros K
    J Psychiatry Neurosci; 1992 Mar; 17(1):1-14. PubMed ID: 1349823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of lamotrigine to clozapine in inpatients with chronic psychosis.
    Heck AH; de Groot IW; van Harten PN
    J Clin Psychiatry; 2005 Oct; 66(10):1333. PubMed ID: 16259551
    [No Abstract]   [Full Text] [Related]  

  • 5. Time course of antipsychotic effects of neuroleptic drugs.
    Keck PE; Cohen BM; Baldessarini RJ; McElroy SL
    Am J Psychiatry; 1989 Oct; 146(10):1289-92. PubMed ID: 2571305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A naturalistic outcome study of risperidone treatment among hospital patients.
    Negrón AE; Leiderman EA; Parkadavil M; Cienfuegos A; Javitt DC
    Psychiatr Serv; 1996 Oct; 47(10):1118-20. PubMed ID: 8890343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of symptoms in neuroleptic-naive patients with schizophrenia and related psychotic disorders before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Psychiatry Res; 2001 Dec; 105(1-2):97-105. PubMed ID: 11740979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of gender differences in neuroleptic response in patients with schizophrenia.
    Pinals DA; Malhotra AK; Missar CD; Pickar D; Breier A
    Schizophr Res; 1996 Dec; 22(3):215-22. PubMed ID: 9000318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
    Van Ree JM; Verhoeven WM; Van Praag HM; De Wied D
    Mod Probl Pharmacopsychiatry; 1981; 17():266-78. PubMed ID: 6173744
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical predictors of relapse following neuroleptic withdrawal.
    Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
    Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness.
    Rabinowitz J; Levine SZ; Medori R; Oosthuizen P; Koen L; Emsley R
    Schizophr Res; 2008 Mar; 100(1-3):359-60. PubMed ID: 18077138
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of activation procedures on neuroleptic-induced akathisia.
    Fleischhacker WW; Miller CH; Barnas C; Bergmann K; Perovich R; Alvir JM; Lieberman JA; Kane JM
    Br J Psychiatry; 1993 Dec; 163():781-4. PubMed ID: 7905775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic treatment of the psychotic symptoms in schizophrenia].
    Goldchluk A
    Vertex; 2002; 13 Suppl 1():4-11. PubMed ID: 12122421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic principles for differential therapy of psychoses].
    Hell D; Bridler R
    Praxis (Bern 1994); 2001 May; 90(22):975-80. PubMed ID: 11450185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment.
    Sharma RP; Bissette G; Janicak P; Davis JM; Nemeroff CB
    Schizophr Res; 1994 Sep; 13(2):173-7. PubMed ID: 7986775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
    Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
    Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
    [No Abstract]   [Full Text] [Related]  

  • 20. Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics.
    de Haan L; Lavalaye J; Booij J; Linszen D
    Am J Psychiatry; 2005 Aug; 162(8):1544-5. PubMed ID: 16055785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.